Tag: MCI
-
Biopharma Bankruptcies Peak Amid Ongoing Financial Difficulties
In 2023, the biopharma sector saw its highest bankruptcy rates in over a decade, with continued issues into 2024. Factors include rising interest rates and economic uncertainties affecting fundraising. Notable bankruptcies include Eiger BioPharmaceuticals and Gritstone bio. Industry experts predict further challenges ahead as conditions remain unfavorable for capital acquisition. In 2023, the biopharmaceutical sector…